Manhattan Research, a global healthcare and pharmaceutical market research company, today announced the release of Taking the Pulse® Europe v8.0, its European physician study and strategic advisory service. It offers in-depth market data and analysis of how physicians across Western Europe integrate the Internet and technology into their practises. Taking the Pulse® Europe also looks at key trends in pharma company/sales rep interactions and electronic detailing.
According to the study, European physicians are more reliant than ever on technology - over 80% who are online reported that the Internet is essential to their practice. On the Web 2.0 front, physician-only social networks potential is high, with nearly two-thirds of online physicians interested in joining this type of community. Also, about two-thirds of physicians online use Wikipedia as a medical resource monthly or more often - and they're even recommending it to patients.
Most Visited Physician Websites in 2008
United Kingdom - British Medical Journal (BMJ.com)
Germany - DocCheck (doccheck.com)
France - Univadis (univadis.fr)
Spain - Diario Medico (diariomedico.com)
Italy - Ministero della Salute (ministerosalute.it)
Among physicians using the Internet for professional purposes
Taking the Pulse® Europe v8.0 was fielded in Q4 2008 among 1,000 European practising physicians from the United Kingdom, Germany, Spain, Italy, and France. For more information, visit http://www.manhattanresearch.com/products/physician/EUphysicians.aspx
To download Manhattan Research's complimentary European Opinion Leader Roundtable, visit http://www.manhattanresearch.com/research/roundtables/european-roundtable-2008.aspx
About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the U.S., Europe, and Asia. Broad research is complemented by targeted analysis among more than 100 consumer therapeutic segments and 25 physician specialist segments.
For information, visit http://www.manhattanresearch.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.
European Physician Tech Tools of the Trade - Wikipedia and Social Networking?
- Details
- Category: Research
Business & Industry
- Bayer Foundation announces Science Awards winners of 2024
- GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
- Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
Research & Development
- Scientists discover how specific E. coli bacteria drive colon cancer
- An old drug with new tricks
- New anti-cancer agent works without oxygen
- Researchers discovered a cancer mechanism that can eliminate tumors - even those resistant to immunotherapy
- Implantable microparticles can deliver two cancer therapies at once
- Unique multidomain enzymes from bacteria
- Immune cell discovery offers new potential for cancer immunotherapy
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease